Case files from Stanford University Medical Center: The initial presentation of HIV-1 infection - Where public and personal health meet

MedGenMed Medscape General Medicine

Volumn 8, Issue 1, 2006, Pages

  Liu, Minghsun ^a   Holodniy, Mark ^a   Zolopa, Andrew R ^a   Shafer, Robert W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; DOXORUBICIN; EFAVIRENZ; EMTRICITABINE; PREDNISONE; TENOFOVIR;

ADULT; ARTICLE; BONE MARROW BIOPSY; BRONCHOSCOPY; CASE REPORT; CELL PROLIFERATION; CLINICAL FEATURE; DISEASE DURATION; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; INGUINAL LYMPH NODE; KAPOSI SARCOMA; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MALE; SPINDLE CELL; UNIVERSITY; VIRUS TITRATION; FATALITY; LUNG TUMOR;

ADULT; FATAL OUTCOME; HIV INFECTIONS; HIV-1; HUMANS; LUNG NEOPLASMS; MALE; SARCOMA, KAPOSI;

EID: 32544446001     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol. 2005;23:5224-5228. Abstract
2. Leidner RS, Aboulafia DM. Recrudescent Kaposi's Sarcoma After initiation of HAART: A Manifestation of Immune Reconstitution Syndrome. AIDS Patient Care STDS. 2005,19:849-858
3. Stebbing J. Portsmouth S. Gazzard B. How does HAART lead to the resolution of Kaposi's sarcoma? J Antimicrob Chemother. 2003;51:1095-1098.
4. Centers for Disease Control and Prevention. Cases of HIV/AIDS amone persons age 13 and older. by year of diagnosis and transmission cateeory. 2000 - 2003 - 33 areas wvith confidential name-based HIV infection reporing. HIV/AIDS Surveill Rep. 2005;15:1-46.
5. Viard JP, Mocroft A. Chiesi A, et al. Infuence of age on CD4 oil recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J. Infect Dis. 2001;183:1290-1294. Abstract
6. Gandhi R, Chan E. Spritzler J. et al. Imumunologic outcomes after antiretroviral therapy in HIV+subjects in ACTG 384. Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, February 22-25, 2005; Boston, Massachusetts, Abstract 610.
7. Wyen C, Hoffmann C. Schmeisser N, et al. Progressive multifocal leukencephalopaty in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Sypdr. 2004:37:1263-1268. Abstract.
8. Yarchoan R. Tosato G. Little RF. Therapy insight: AIDS-related malignancies-the influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol. 2005;2:406-415; quiz 423.
9. Brenner B. Roger M, Moisi D. et al. Transmission events within risk groups following primary HIV-1 infection (PHI) in Quebec (1998-2005). Antivir Ther. 2005;10:S125.
10. Paltiel AD, Weinstein MC. Kimmel AD. et al. Expanded screening for HIV in the United States-an analysis of cost-effectiveness. N Engl J Med. 2005:352:586-595, Abstract.
11. Sanders GD. Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352-570-585. Abstract.